COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study
A subset of patients with severe COVID-19 develops hyperinflammatory syndrome, which might contribute to morbidity and mortality. The study included 2...
Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study
Hydroxychloroquine has received negative publicity for adverse events associated with its authorization for emergency use to treat patients with COVID...
Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study
Hydroxychloroquine is one of several agents being evaluated in the treatment of severe acute respiratory syndrome coronavirus 2. Overall mortality was...
Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study
Otilimab inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) This is a key driver in immune-mediated inflammatory conditions. We aimed...
MRI of the joint and evaluation of the granulocyte–macrophage colony-stimulating factor–CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study
Otilimab is a human monoclonal antibody that inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) This study was done at nine sites acro...
Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records
Biopsy length for diagnosis of giant cell arteritis is debated. We reviewed temporal artery biopsies from a 10-year period in Alberta to identify an i...
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Severe COVID-19 is characterized by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential be...
Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study
A subset of patients with COVID-19 develops a hyperinflammatory syndrome that has similarities with other hyperinflammatory disorders. We developed a...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
